Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

Vaccine

Volumn 28, Issue 41, 2010, Pages 6698-6703

  Mordmüller, Benjamin ^a,b   Szywon, Katja ^a,b   Greutelaers, Benedikt ^a,b   Esen, Meral ^a,b   Mewono, Ludovic ^a,b   Treut, Carolin ^a,b   Mürbeth, Raymund E ^a,b   Chilengi, Roma ^c   Noor, Ramadhani ^c   Kilama, Wen L ^c   Imoukhuede, Egeruan Babatunde ^d   Imbault, Nathalie ^d   Leroy, Odile ^d   Theisen, Michael ^e   Jepsen, Søren ^f   Milligan, Paul ^g   Fendel, Rolf ^a,b   Kremsner, Peter G ^a,b   Issifou, Saadou ^a,b  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c African Malaria Network Trust   (Tanzania)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f STATENS SERUM INSTITUT   (Denmark)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Malaria immunity; Malaria vaccine; Phase I clinical trial

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; GMZ2 VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; RABIES VACCINE; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GABON; HEADACHE; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALAISE; MALARIA; MALE; MEMORY CELL; MYALGIA; NAUSEA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; VOMITING;

ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; DOUBLE-BLIND METHOD; GABON; HUMANS; IMMUNOLOGIC MEMORY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 77956481961     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.085     Document Type: Article

References (16)

1. Mendis K., Rietveld A., Warsame M., Bosman A., Greenwood B., Wernsdorfer W.H. From malaria control to eradication: the WHO perspective. Trop Med Int Health 2009, 7:802-809.
2. Targett G.A., Greenwood B.M. Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008, 1(Suppl.):S10.
3. Mordmüller B., Kremsner P.G. Malarial parasites vs. antimalarials: never-ending rumble in the jungle. Curr Mol Med 2006, 2:247-251.
4. Dalton J.P., Mulcahy G. Parasite vaccines-a reality?. Vet Parasitol 2001, 1-3:149-167.
5. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 9443:1411-1420.
6. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 7:e2636.
7. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 3:297-308.
8. Theisen M., Soe S., Oeuvray C., Thomas A.W., Vuust J., Danielsen S., et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998, 1:11-17.
9. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., Bottius E., Kaidoh T., Aikawa M., et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 5:1594-1602.
10. Soe S., Theisen M., Roussilhon C., Aye K., Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004, 1:247-252.
11. Meraldi V., Nebié I., Tiono A.B., Diallo D., Sanogo E., Theisen M., et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004, 6-7:265-272.
12. Carvalho L.J.M., Alves F.A., Bianco C., Oliveira S.G., Zanini G.M., Soe S., et al. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 2005, 2:242-248.
13. Esen M., Kremsner P.G., Schleucher R., Gässler M., Imoukhuede E.B., Imbault N., et al. Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009, 49:6862-6868.
14. Wildling E., Winkler S., Kremsner P.G., Brandts C., Jenne L., Wernsdorfer W.H. Malaria epidemiology in the province of Moyen Ogoov, Gabon. Trop Med Parasitol 1995, 2:77-82.
15. Planche T., Krishna S., Kombila M., Engel K., Faucher J.F., Ngou-Milama E., et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 2001, 5:599-602.
16. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 5601:2199-2202.